Maternal serum alpha-fetoprotein screening.

Pediatric Annals
B K Burton

Abstract

Maternal serum alpha-fetoprotein screening should be offered to all patients as a routine component of prenatal care. The benefits of MSAFP screening have far exceeded early expectations. This technology not only provides an efficient and cost-effective method of screening for neural tube defects that is applicable to all pregnancies but also provides the physician with important information relevant to a number of other birth defects and complications of pregnancy. Our knowledge of variables affecting MSAFP levels measured during pregnancy is rapidly evolving, and further refinements in the application of MSAFP screening will almost certainly occur. Such refinements can serve only to extend the benefits of this new and very valuable technology in improving the health and well being of mothers and infants.

References

Feb 1, 1987·American Journal of Obstetrics and Gynecology·G E Palomaki, J E Haddow
Nov 1, 1988·American Journal of Obstetrics and Gynecology·A MilunskyK Currie
Dec 1, 1988·American Journal of Obstetrics and Gynecology·M I EvansJ J LaFerla
Jun 15, 1983·American Journal of Obstetrics and Gynecology·B K BurtonL H Nelson
Apr 1, 1984·American Journal of Obstetrics and Gynecology·I R MerkatzW E Johnson

❮ Previous
Next ❯

Citations

Feb 1, 1990·Pediatric Annals·G N Wilson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.